NASDAQ: EVOEvotec Se Stock
$3.07+0.07 (+2.33%)
Updated Dec 11, 2025
EVO Price
$3.07
Fair Value Price
N/A
Market Cap
$1.09B
52 Week Low
$2.84
52 Week High
$5.10
P/E
-5.94x
P/B
1.17x
P/S
1.45x
PEG
N/A
Dividend Yield
N/A
Revenue
$879.45M
Earnings
-$187.04M
Gross Margin
10.8%
Operating Margin
-15.47%
Profit Margin
-21%
Debt to Equity
1.22
Operating Cash Flow
$2M
Beta
1.06
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
EVO Overview
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine EVO's potential to beat the market
- EVO doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
EVO
RankedUnranked of 57
RankedUnranked of 57
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $3.68 | A | |
| $48.36 | A | |
| $35.79 | A |
Be the first to know about important EVO news, forecast changes, insider trades & much more!
EVO News
Overview
Due Diligence Score
–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how EVO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
EVO is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
EVO is good value based on its book value relative to its share price (1.17x), compared to the US Drug Manufacturers - Specialty & Generic industry average (2.25x)
P/B vs Industry Valuation
EVO is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more EVO due diligence checks available for Premium users.
Valuation
EVO fair value
Fair Value of EVO stock based on Discounted Cash Flow (DCF)
Price
$3.07
Fair Value
-$2.36
Undervalued by
230.24%
EVO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
EVO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-5.94x
Industry
-3.37x
Market
45.84x
EVO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.17x
Industry
2.25x
EVO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
EVO's financial health
Profit margin
Revenue
$192.8M
Net Income
-$50.7M
Profit Margin
-26.3%
EVO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
EVO's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$2.1B
Liabilities
$1.1B
Debt to equity
1.22
EVO's short-term assets ($922.23M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
EVO's short-term assets ($922.23M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
EVO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$85.7M
Investing
-$59.7M
Financing
$10.1M
EVO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
EVO vs Pharmaceutical Stocks
Evotec Se Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.